Break the Liver Biopsy Habit

Similar documents
Supplementary Online Content

Non-Invasive Testing for Liver Fibrosis

When to Treat: Staging Liver Disease David L. Thomas, MD, MPH

Non-Invasive Assessment of Liver Fibrosis. Patricia Slev, PhD University of Utah Department of Pathology

Laboratory Tests and Diagnostic Procedures in Liver Disease: Adventures in Liverland

Faculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014

Noninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD

Monitoring Hepatitis C

Liver 102: Injury and Healing

National Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008

Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease

Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease

MP Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease

Initial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH

The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis

NONINVASIVE TECHNIQUES FOR EVALUATION AND MONITORING OF CHRONIC LIVER DISEASE

NON INVASIVE EVALUATION OF DISEASE PROGRESSION IN CHRONIC LIVER DISEASES

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER

Pretreatment Evaluation

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

CLINICAL STUDIES. Liver International ISSN

Case #1. Digital Slides 11/6/ year old woman presented with abnormal liver function tests. Liver Biopsy to r/o autoimmune hepatitis

Bio Predictive. FibroTest/FibroSure Scientific Publications. Houot 2015 FibroTest, TE, FIB-4, APRI Meta-analysis

New Tools for Assessing Disease Sererity, progression and regression in HBV and HCV

Module 1 Introduction of hepatitis

WHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust

NAFLD and NASH: The Not-So-New Kids on the Block

The Future is Here Now!

Hepatology For The Nonhepatologist

*APHP: Hôpital Beaujon Professor P Bedossa, Dr F Degos, Professor P Marcellin, Professor

The New World of HCV Therapy

Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy

Management of Liver Diseases: A Nonhepatologist s Viewpoint

Clinical Policy Title: Serum biomarkers for liver fibrosis in chronic hepatitis

Clinical cases: HIV/HCV coinfection

Update on systemic therapies and emerging treatments How do I choose a systemic agent?

Section: Laboratory Last Reviewed Date: June Policy No: 47 Effective Date: August 1, 2013

Pretreatment assessment of Chronic Hepatitis C and Compensated Cirrhosis and Indications for Therapy

Chewing the Fat on Fatty Liver Mike Kolber MD, CCFP, MSc PEIP 2018

Improved Hepatic Fibrosis Grading Using Point Shear Wave Elastography and Machine Learning

NHSScotland is required to consider the Scottish Health Technologies Group (SHTG) advice.

Pretreatment Evaluation

Patterns of abnormal LFTs and their differential diagnosis

The New World of HCV Therapy

CASES FOR DISCUSSION. Yohannes B

Current practice of methotrexate use for psoriasis: results of a worldwide survey among dermatologists

The Liver for the Nonhepatologist

Transient elastography in chronic viral liver diseases

Top Hepatology Findings/Papers of 2013

Learning Objectives. After attending this presentation, participants will be able to:

Clinical Policy Title: Serum biomarkers for liver fibrosis in chronic hepatitis

A Rational Evidence-based Approach to Abnormal Liver Tests

In response to an enquiry from the Scottish Clinical Biochemistry Managed Diagnostic Network

Alternatives to Liver Biopsy for Assessing Liver Disease

Protocol for daclatasvir (Daklinza ) Approved October 2015 (updated February 2018)

HEPATIC FIBROSIS AND CIRrhosis

Study population The study population comprised patients with psoriasis who were receiving long-term methotrexate.

In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease

New HCV reimbursement criteria Chronic hepatitis C regardless of fibrosis stage if:

Assessment of Liver Stiffness by Transient Elastography in Diabetics with Fatty Liver A Single Center Cross Sectional observational Study

AASLD Immune tolerant phase HBV NAFLD diagnostic HCC

Pretreatment Evaluation

Normal ALT for men 30 IU/L 36% US males abnormal. Abnl ALT. Assess alcohol use/meds. Recheck in 6-8 weeks. still pos

Invasive. Sampling error. Interobserver variability. Nondynamic evaluation of

Hepatocellular Carcinoma: Epidemiology and Screening

The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases

CITY AND HACKNEY CCG ABNORMAL LIVER FUNCTION TESTS (LFTs) in ADULTS

New York State HCV Provider Webinar Series. Overview of Fibrosis Staging, Child s Pugh, MELD Scores

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea

Page: 1 of 19. Noninvasive Techniques for the Evaluation and Monitoring of Patients with Chronic Liver Disease

Navigating The Prior Authorization Approval Process. Kristin Webb, RPCA University at Buffalo

Navigating The Prior Authorization Approval Process

Managing abnormal LFTs in Primary care

INHSU th International Symposium on Hepatitis Care In Substance Users

ASSESSMENT PRIOR TO TREATMENT DO WE NEED IL28B TESTING?

Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR

NASH : Diagnosis and investigation. VII Workshop international, Curitiba, Brazil 29/08/2014

EVALUATION OF ABNORMAL LIVER TESTS

Part I. Prior Authorization Criteria and Policy

Transient elastography in chronic liver diseases of other etiologies

LFTs: an update A MacGilchrist PLIG meeting 31st January 2019

2. Liver blood tests and what they mean p2 Acute and chronic liver screen

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow

Research Article Liver Stiffness Measurement in Psoriasis: Do Metabolic or Disease Factors Play the Important Role?

Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients

Making the best use of liver biopsy: clinical perspective. Steve Ryder Wolfson Digestive Diseases Centre University of Nottingham

Hepatitis C Update on New Treatments

Patterns of abnormal LFTs and their differential diagnosis

New HCV reimbursement criteria Chronic hepatitis C regardless of fibrosis stage if:

Prior Authorization Guideline

Section: Laboratory Last Reviewed Date: May Policy No: 47 Effective Date: August 1, 2014

Research Elastography: Liver

New HCV reimbursement criteria Chronic hepatitis C regardless of fibrosis stage if:

Combination Nonbiologic Therapy in Psoriasis. Sushil Tahiliani, MBBS, MD

Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing?

Medical Policy Non-invasive Tests for Hepatic Fibrosis

Prior Authorization Guideline

Transcription:

Break the Liver Biopsy Habit Dirk Elston MD Professor and Chairman Department of Dermatology and Dermatologic Surgery Medical University of South Carolina No conflict of interest

Father of one of my nurses: has insurance, but pays out of pocket for medications

Cleared 99% with MTX liquid 12.5 mg/week It costs him $8 per month, and he is delighted with the results He initially was afraid of MTX because he almost bled to death after a liver biopsy and wants to avoid another biopsy He was always told the biopsy was mandatory

What would you do? A. Treat with no lab work B. Follow LFTs C. Ultimatum: at 1.5 gm, no bx/no MTX D. Follow procollagen 3 terminal peptide E. Follow Fibrosure (NASH or HepC)

ACR vs AAD Recommendations are different Are liver biopsies necessary? At what dose? Only if LFTs are abnormal? Psoriasis are different from RA patients Higher doses and higher incidence of metabolic syndrome, obesity, ETOH use

MTX-induced fibrosis Not an inflammatory process Concurrent hepatitis may or may not exist LFTs measure inflammatory damage Fibrosure involves predictive modelling based on patient characteristics (many of which we already know for psoriasis patients)

Fibrosure (Fibrotest) Artificial intelligence algorithm using α2- macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, γ-glutamyl transpeptidase (GGT), +/- ALT, with a patient s age and gender Reliable assessment of risk in HCV and NASH Should not be used for Gilbert disease, acute viral hepatitis, drug-induced hepatitis, genetic liver disease, autoimmune hepatitis, and/or extrahepatic cholestasis.

Hepatic fibrosis with MTX in RA Using AAD recommendations, 66 RA patients underwent 110 liver biopsies (ACR criteria would have resulted in 18 biopsies in 15 patients) Found 1 patient with cirrhosis who would have been missed with ACR criteria (NIDDM) Arthritis Rheum 1995; 38:1115-9

AAD vs ACR Recommendations Does this mean that 2% of cases of cirrhosis are missed in RA pts using ACR criteria? Would the percentage be higher for psoriasis patients given their higher overall risk? How many cases of cirrhosis are too many?

Danish Experience University of Aarhus Serial liver biopsies in 25 patients Subsequent specimens tended to be same or lower grade fibrosis 10 year follow-up One 84 year old woman died of liver failure despite normal LFTs for 8 years after last biopsy (normal) Dermatologica 1987; 107:418-9 Dermatology 1996 192:343-6

Danish Experience University of Aarhus Change of practice - Procollagen3 terminal peptide measurement 10 year follow-up since introduction of P3P measurement No episodes of significant fibrosis or cirrhosis JAAD 2000; 42:531-4

Manchester Guidelines Test quarterly Normal: below 4.2 2 values above 8 or one above 11: D/C or reduce dose Joint disease may cause high P3P unrelated to liver fibrosis

Transient Elastography and FibroTest Pulse-echoultrasonography to measure liver stiffness FibroTest (Fibrosure) is an indirect serum marker of hepatic fibrosis Serial procollagen 3 peptide (P3P) results were recorded The Use of Transient Elastography and FibroTest for Monitoring Hepatotoxicity in Patients Receiving Methotrexate for Psoriasis. JAMA Dermatol. 2014 150:856-62

Transient Elastography and FibroTest 77 patients (65% with valid TE assessment) 9 (18%) had an abnormal result Being overweight or obese increased the possibility of an invalid TE result and body mass index and age were correlated with abnormal TE results. Seventy-one patients received FibroTest 16% had an abnormal result

Transient Elastography and FibroTest No correlation between PIIINP levels and TE results or FibroTest results. Two patients had hepatic fibrosis The need for liver biopsy could be reduced if abnormalities in at least 2 tests (serial PIIINP, TE, or FibroTest) re required before biopsy is considered. 1 patient with grade 3a portal fibrosis: normal FibroTest 12 months post-mtx 1 with 3b sinusoidal fibrosis: invalid TE

Meta-analysis P3P (most extensively validated method) Sensitivity 77.3%, specificity 91.5% PPV and NPV depend on prevalence fibrosis FibroTest Sensitivity 83%, specificity 61% Fibroscan Sensitivity 50%, specificity 88% Recommended all 3 in combination J Eur Acad Dermatol Venereol. 2011 May;25 Suppl 2:12-8. doi:10.1111/j.1468-3083.2011.03991.x.

More Recent Meta-analysis Sensitivity and specificity 74% and 77% for P3P 60% and 80% for Fibroscan 55% and 49% for ultrasound 38% and 83% for LFTs Overall quality of data poor BJD 2014 Jun;170(6):1237-47. doi: 10.1111/bjd.12905.

Emerging Tests Urine markers N-cadherin, inter-alpha-trypsin inhibitor heavy chain H4, haptoglobin and serotransferrin found in urine of psoriasis patients with high cumulative MTX dose Validation needed Toxicol Lett. 2013 Aug 29;221(3):219-24.

Eur Acad Dermatol Venereol. 2014 Apr 15. doi: 0.1111/jdv.12495. [Epub ahead of print] Worldwide survey 481 dermatologists from 63 countries Almost all monitored CBC, LFTs and renal function tests P3P and transient elastography used by a minority Many stopped the drug at 2 gm and expressed concern about safety

British Consultant Dermatologists Almost all monitored CBC, LFTs, RFTs 71% now measure P3P 12% reported patients with irreversible liver damage 49 deaths 18 myelosuppression 6 pulmonary fibrosis 2 liver failure Br J Dermatol. 2008 Apr;158(4):793-800.

Conclusions It s time to break the liver biopsy habit The question is how to do it LFTs aren t very good P3P, FibroSure, and Fibroscan are better New tests are being developed Don t forget the risks of myelosuppression and pulmonary fibrosis